Maraviroc and Rifabutin interaction

Maraviroc and Rifabutin: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Rifabutin label · effective 2026-09-01

Major

Therefore, co-administration with antiretroviral and anti-HCV drugs metabolized by CYP3A is not recommended or there may be a need to increase the dose of antiretroviral or anti-HCV drugs (see PRECAUTIONS-Drug Interactions ).

Warningsby drug classView label on DailyMed
Moderate

The concomitant use of protease inhibitors may require at least a 50% reduction in rifabutin dose, and depending on the protease inhibitor, an adjustment of the antiretroviral drug dose.

Warningsby drug classView label on DailyMed
Moderate

Co-administration with antiretroviral drugs metabolized by CYP3A, including but not limited to products containing bictegravir, elvitegravir, oral rilpivirine, or doravirine and anti-HCV drugs including but not limited to sofosbuvir (alone or in combination) may decrease plasma concentrations of those drugs, which may lead to loss of virologic response and possible…

Warningsby drug classView label on DailyMed
Minor

Antiretroviral and Anti-HCV Drug Interactions Protease inhibitors act as substrates or inhibitors of CYP3A4 mediated metabolism.

Warningsby drug classView label on DailyMed
Minor

For further recommendations, please refer to the most recent prescribing information of the antiretrovirals or anti-HCV drugs or contact the specific manufacturer.

Warningsby drug classView label on DailyMed

From the Maraviroc (SELZENTRY) label · effective 2023-11-10

Moderate

• If patients with severe renal impairment or ESRD receiving SELZENTRY (without concomitant CYP3A inducers or inhibitors) experience postural hypotension, the dose of SELZENTRY should be reduced from 300 mg twice daily to 150 mg twice daily.

Warnings and precautionsby drug classView label on DailyMed
Moderate

• Coadministration with CYP3A inducers, including efavirenz, may decrease the concentration of SELZENTRY.

Drug interactionsby drug classView label on DailyMed
Minor

The pharmacokinetics of maraviroc are likely to be modulated by inhibitors and inducers of CYP3A and P-gp and may be modulated by inhibitors of OATP1B1 and MRP2.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.